U.S. Markets closed

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.93-0.27 (-2.65%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors
    GlobeNewswire

    Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company’s Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F.

  • Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?
    Zacks

    Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

    Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
    GlobeNewswire

    Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA

    Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Recognizes High Unmet Medical Need in ERT Treated Late-Onset Pompe Disease Patients Positive Scientific Opinion Includes MHRA Review of AT-GAA Phase 3 PROPEL Study Data PHILADELPHIA and MARLOW, United Kingdom, June 08, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated glo